Regulation of PGE(2) and PGI(2) release from human umbilical vein endothelial cells by actin cytoskeleton

Disruption of microfilaments in human umbilical vein endothelialcells (HUVEC) with cytochalasin D (cytD) or latrunculin A (latA)resulted in a 3.3- to 5.7-fold increase in total synthesis ofprostaglandin E₂ (PGE₂) and a 3.4- to 6.5-foldincrease in prostacyclin (PGI₂) compared with controlcells. Disruption of the microtubule network with nocodazole orcolchicine increased synthesis of PGE₂ 1.7- to 1.9-fold andPGI₂ 1.9- to 2.0-fold compared with control cells.Interestingly, however, increased release of PGE₂ andPGI₂ from HUVEC into the media occurred only when microfilaments were disrupted. CytD treatment resulted in 6.7-fold morePGE₂ and 3.8-fold more PGI₂ released from HUVECcompared with control cells; latA treatment resulted in 17.7-fold more PGE₂ and 11.2-fold more PGI₂ released comparedwith control cells. Both increased synthesis and release ofprostaglandins in response to all drug treatments were completelyinhibited by NS-398, a specific inhibitor of cyclooxygenase-2 (COX-2).Disruption of either microfilaments using cytD or latA or ofmicrotubules using nocodazole or colchicine resulted in a significantincrease in COX-2 protein levels, suggesting that the increasedsynthesis of prostaglandins in response to drug treatments may resultfrom increased activity of COX-2. These results, together with studies demonstrating a vasoprotective role for prostaglandins, suggest thatthe cytoskeleton plays an important role in maintenance of endothelialbarrier function by regulating prostaglandin synthesis and release from HUVEC.